IBCL-123 inMIND: A Phase 3 Study of Tafasitamab Plus Lenalidomide and Rituximab Versus Placebo Plus Lenalidomide and Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)
作者
Laurie Helen Sehn,Kai Hübel,Stefano Luminari,Antonio Salar,Björn Engelbrekt Wahlin,Ajay K. Gopal,Christophe Marc Bonnet,Shankara Paneesha,Marek Trněný,Hafsat Mashegu,Christine Francis Lihou,Lulu L Cheng,Christian W. Scholz